The Updated Information About SINGULAIR DRUG and other Leukotriene Inhibitors
Singulair (Montelukast) was introduced in 1998. Generic Singulair is indicated for the patients on asthma aged from children of 12 months and older. This Asthma medicine is used for the relief of symptoms of seasonal allergic rhinitis (SAR) in adults and children 2 years and older, and for the relief of symptoms of perennial allergic rhinitis (PAR) in adults and children 6 months and older. The safety and efficacy profile of Montelukast tablets is verified by clinical trials, and by a review of event reports, including the types of neuropsychiatric events.
In response to the U.S. Food & Drug Administration (FDA) June 12, 2009 Communication Merck & Co., Inc. issued the following statement addressing updated information on leukotriene inhibitors, including Singulair drug.
Merck will continue to work with the FDA to revise the prescribing information for Singulair medication in the United States to include a precaution related to post-marketing adverse events.
According to Scott Korn, M.D.,vice president, Clinical Risk Management and Safety Surveillance, Merck Research Laboratories, Montelukast asthma medicine an important treatment option for patients suffering from either asthma or allergic rhinitis.
Merck intends to inform patients, parents and health care providers about Singulair medicine and to help in appropriate treatment choices. Patients should talk to the specialists about the benefits and risks before starting or stopping treatment with asthma and allergies medications.
Singulair 5 mg has been prescribed to tens of millions of patients with asthma and allergic rhinitis. And Merck is confident in the efficacy and safety of Singulair medication that was approved more than 11 years ago.
You can buy cheap Singulair in our online pharmacy.
